FLT3L and plerixafor combination increases hematopoietic stem cell mobilization and leads to improved transplantation outcome

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 3, 2014, Pages 309-313

  He, Shun ^a,b   Chu, Jianhong ^b   Vasu, Sumithira ^a,b   Deng, Youcai ^b   Yuan, Shunzong ^b,c   Zhang, Jianying ^d   Fan, Zhijin ^b   Hofmeister, Craig C ^a,b   He, Xiaoming ^b,e   Marsh, Henry C ^f   Devine, Steven M ^a,b   Yu, Jianhua ^a,b  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c Beijing 307 Hospital   (China)

^d OHIO STATE UNIVERSITY   (United States)

^e The Ohio State University   (United States)

^f Celldex Therapeutics Inc   (United Kingdom)

Author keywords

Cell mobilization; FLT3L; Plerixafor; Transplantation

Indexed keywords

FLT3 LIGAND; GRANULOCYTE COLONY STIMULATING FACTOR; PLERIXAFOR;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CONTROLLED STUDY; DRUG POTENTIATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LONG TERM SURVIVAL; MONOTHERAPY; MOUSE; NATURAL KILLER CELL; NONHUMAN; PHENOTYPE; PLASMACYTOID DENDRITIC CELL; REGULATORY T LYMPHOCYTE; STEM CELL MOBILIZATION; TREATMENT OUTCOME;

CELL MOBILIZATION; FLT3L; PLERIXAFOR; TRANSPLANTATION;

ANIMALS; DENDRITIC CELLS; DRUG COMBINATIONS; DRUG SYNERGISM; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HETEROCYCLIC COMPOUNDS; HUMANS; INJECTIONS, INTRAPERITONEAL; KILLER CELLS, NATURAL; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; RECOMBINANT PROTEINS; SURVIVAL ANALYSIS; T-LYMPHOCYTES, REGULATORY; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; WHOLE-BODY IRRADIATION;

EID: 84896816935     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.11.024     Document Type: Article

References (27)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63:11-30.
2. Devine S.M., Vij R., Rettig M., et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood 2008, 112:990-998.
3. Brasel K., McKenna H.J., Charrier K., et al. Flt3 ligand synergizes with granulocyte-macrophage colony-stimulating factor or granulocyte colony-stimulating factor to mobilize hematopoietic progenitor cells into the peripheral blood of mice. Blood 1997, 90:3781-3788.
4. de Kruijf E.J., Hagoort H., Velders G.A., et al. Hematopoietic stem and progenitor cells are differentially mobilized depending on the duration of Flt3-ligand administration. Haematologica 2010, 95:1061-1067.
5. Anandasabapathy N., Hurley A., Breton G., et al. Aphase 1 trial of the hematopoietic growth factor CDX-301 (rhuFlt3L) in healthy volunteers. Biol Blood Marrow Transplant 2013, 19:S112-S113.
6. Ferraro F., Lymperi S., Mendez-Ferrer S., et al. Diabetes impairs hematopoietic stem cell mobilization by altering niche function. Sci Transl Med 2011, 3:104ra101.
7. Lyman S.D., James L., Johnson L., et al. Cloning of the human homologue of the murine flt3 ligand: a growth factor for early hematopoietic progenitor cells. Blood 1994, 83:2795-2801.
8. Brasel K., McKenna H.J., Morrissey P.J., et al. Hematologic effects of flt3 ligand invivo in mice. Blood 1996, 88:2004-2012.
9. Gerlach L.O., Skerlj R.T., Bridger G.J., et al. Molecular interactions of cyclam and bicyclam non-peptide antagonists with the CXCR4 chemokine receptor. JBiol Chem 2001, 276:14153-14160.
10. Broxmeyer H.E., Orschell C.M., Clapp D.W., et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. JExp Med 2005, 201:1307-1318.
11. Glass B., Uharek L., Zeis M., et al. Allogeneic peripheral blood progenitor cell transplantation in a murine model: evidence for an improved graft-versus-leukemia effect. Blood 1997, 90:1694-1700.
12. Zeng D., Dejbakhsh-Jones S., Strober S. Granulocyte colony-stimulating factor reduces the capacity of blood mononuclear cells to induce graft-versus-host disease: impact on blood progenitor cell transplantation. Blood 1997, 90:453-463.
13. Yu J., Mao H.C., Wei M., et al. CD94 surface density identifies a functional intermediary between the CD56bright and CD56dim human NK-cell subsets. Blood 2010, 115:274-281.
14. Guimond M., Freud A.G., Mao H.C., et al. Invivo role of Flt3 ligand and dendritic cells in NK cell homeostasis. JImmunol 2010, 184:2769-2775.
15. Maraskovsky E., Brasel K., Teepe M., et al. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. JExp Med 1996, 184:1953-1962.
16. Strobl H., Bello-Fernandez C., Riedl E., et al. flt3 ligand in cooperation with transforming growth factor-beta1 potentiates invitro development of Langerhans-type dendritic cells and allows single-cell dendritic cell cluster formation under serum-free conditions. Blood 1997, 90:1425-1434.
17. Yang L., Bryder D., Adolfsson J., et al. Identification of Lin(-)Sca1(+)kit(+)CD34(+)Flt3- short-term hematopoietic stem cells capable of rapidly reconstituting and rescuing myeloablated transplant recipients. Blood 2005, 105:2717-2723.
18. Schmitz N., Linch D.C., Dreger P., et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996, 347:353-357.
19. Gertz M.A. Current status of stem cell mobilization. Br J Haematol 2010, 150:647-662.
20. Olson J.A., Leveson-Gower D.B., Gill S., et al. NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects. Blood 2010, 115:4293-4301.
21. Rezvani K., Mielke S., Ahmadzadeh M., et al. High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood 2006, 108:1291-1297.
22. Markey K.A., Banovic T., Kuns R.D., et al. Conventional dendritic cells are the critical donor APC presenting alloantigen after experimental bone marrow transplantation. Blood 2009, 113:5644-5649.
23. Toubai T., Malter C., Tawara I., et al. Immunization with host-type CD8{alpha}+ dendritic cells reduces experimental acute GVHD in an IL-10-dependent manner. Blood 2010, 115:724-735.
24. Banovic T., Markey K.A., Kuns R.D., et al. Graft-versus-host disease prevents the maturation of plasmacytoid dendritic cells. JImmunol 2009, 182:912-920.
25. Kerryn Ansell L.F.P. Autograft monocytes: the bad humors of autologous peripheral blood hematopoietic stem cell transplantation. JStem Cell Res Ther 2013, S3:5.
26. Mougiakakos D., Jitschin R., von Bahr L., et al. Immunosuppressive CD14+HLA-DRlow/neg IDO+ myeloid cells in patients following allogeneic hematopoietic stem cell transplantation. Leukemia 2013, 27:377-388.
27. Gabrilovich D.I., Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009, 9:162-174.